Floatz logo

Riluzole

Treatment-resistant Schizophrenia

King's College LondonSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Treatment-resistant Schizophrenia cohort.

Asset / SponsorPhaseRating
Olanzapine
Dr. Stavroula Rakitzi
Phase 4BB
Risperdal
Dr. Stavroula Rakitzi
Phase 4BB
AMISULPRIDE
University of California, Los Angeles
Phase 4BB
Clozapine
Dr. Stavroula Rakitzi
Phase 4BB
Dextromethorphan
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BB

View all 23 →

Same molecule, other indications

Riluzole is also rated in:

amyotrophic lateral sclerosisDormant
BB
Indicative ·
69 / 100
View asset →
major depressive disorderDormant
BB
Indicative ·
68 / 100
View asset →
cerebellar ataxiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →